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Introduction
Isocarboxazid is the only one of the classical monoamine oxidase 
inhibitors (MAOIs), which is marketed in Denmark. In 1980 a paper 
on long-term treatment of depression with isocarboxazid suggested 
that treatment with monoamine oxidase inhibitors like isocarboxazid 
should not be left untried in the case of therapy-resistant depression 
[1]. This is in accordance with the registered indication of the National 
Health Service of Denmark, however, nowadays worded as treatment-
resistant depression (TRD) [2]. Also in the late 1970 a paper stated 
that “the use of MAOIs has been underutilized and a resurgence of 
interest in the MAOIs is timely” [3]. Meanwhile, in the era of newer 
antidepressants from the 1980 isocarboxazid was never routinely used. 
In 2013 the market share of isocarboxazid in Denmark accounted for 
only 262.000 defined daily doses (DDD´s) (0.2%), which corresponds 
to about 400 patients. In comparison 151.601.000 DDD´s (93.9%) 
were prescribed for use of SSRI (selective serotonin reuptake inhibitor) 
antidepressants and other newer antidepressants [4]. 
The reasons for this development were the risk of side effects with 
isocarboxazid, as well as the potential interactions with other drugs 
and certain foods, but also ignorance about how isocarboxazid is 
metabolized in the liver.
The concept of TRD was introduced in 1974 and accordingly TRD is 
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normally defined as an insufficient response to two different antidepressants 
from two separate pharmacological classes [5]. It is generally estimated that 
at least 20% of the depressive patient population is suffering from TRD, 
thus TRD is one of our major health challenges [6,7]. 
As in the late 1970´ies we still estimate the use of MAOIs including 
isocarboxazid to be underutilized [3]. Therefore considering the great 
number of patients with TRD we have found it worthwhile to revisit 
the drug.
The aims of the present review is to give a brief overview of the 
clinical efficacy of isocarboxazid, including in combination with other 
antidepressants, to discuss the mechanisms of action and metabolism, 
to give an account of the adverse effects and interactions and to explain 
how they may be counteracted. 
Abstract
The clinical use of monoamine oxidase inhibitors (MAOIs) like isocarboxazid nowadays is most often seen with 
treatment resistant depression, which is in accordance with the registered indication of the National Health Service 
of Denmark. The clinical use, however, early became restricted and today it covers only a minority of the market for 
antidepressants.
The aim of the present paper is to give a short overview of the clinical efficacy, to review mechanisms of action and 
metabolism of MAOIs, and to discuss how the side effects and interactions with these drugs may be avoided.
A number of clinical trials have documented that MAOIs are effective antidepressants in major depression, including 
in patients with melancholic syndrome. In Denmark the combined use of nortriptyline with isocarboxazid as add-on 
treatment for more than 30 years has proved to be safe and efficient. MAOIs must never be combined with SSRIs and 
serotonergic TCAs. 
The normal dose of isocarboxazid may cause oedema, which can be treated with a supplement of 100-200 mg 
pyridoxine (vitamin B6). Isocarboxazid is metabolized by hydrolysis by the liver enzyme carboxylesterase. In contrast to 
most other antidepressants, the liver enzyme CYP2D6 is not involved in the metabolism of isocarboxazid, which means 
that it can be used in normal dose for all patients.
Treatment with isocarboxazid needs precautions with a number of other drugs and the necessity to avoid certain 
foodstuffs containing excessive amounts of tyramine. Danish patients being treated with isocarboxazid are recommended 
to carry along a simple instruction, containing general advice for health personal and a list of foods to avoid. Treatment 
with isocarboxazid is considered to be a relevant option in treatment-resistant depression and we are today much better 
prepared than we were many years ago to use the drug in our rational pharmacotherapy. 
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The Clinical Efficacy of Isocarboxazid in Monotherapy 
and in Combination with Other Antidepressants 
The clinical efficacy of isocarboxazid was never well established 
in randomized controlled trials [1,8] and for many years the clinical 
specificity of monoamine oxidase inhibitors in so-called atypical 
depression was intensely, however, inconclusively studied [9-11].
In 1991 atypical depression usually characterized by “increased 
duration of sleep, weight gain, blames of others, intrusive character 
deviation and irritability” was also studied with the selective and 
reversible monoamine oxidase inhibitor moclobemide, however, no 
interaction between treatment and atypical or not atypical depression 
was found [11]. A re-analysis of the moclobemide data, however, 
pointed at a clinical specificity of moclobemide with atypical depression 
[12]. More important, in the 1991-study, moclobemide was found to be 
slightly inferior to clomipramine and isocarboxazid [11]. Likewise in a 
prospective clinical practice study from 2001 electroconvulsive therapy 
(ECT), tricyclic antidepressants (TCA) and classical monoamine 
inhibitors were found to be more effective than SSRIs, reversible 
monoamine oxidase inhibitors and antipsychotic drugs in depression 
with melancholic syndrome [13].
Combined use of tricyclic antidepressants and monoamine oxidase 
inhibitors is controversial. In combination treatment amitriptyline often 
was considered as the optimal tricyclic antidepressant with various 
irreversible monoamine oxidase inhibitors like tranylcypromine, 
phenelzine and isocarboxazid [14-16]. Generally it is strongly 
recommended to use the monoamine oxidase inhibitor as an add-on 
treatment to the tricyclic antidepressant and never to combine with 
TCAs in the serotonergic end of the TCA spectrum, like clomipramine 
[2]. Though also later studies used amitriptyline in combination with 
MAOIs [17,18], for more than 30 years the active main metabolite 
of amitriptyline, nortriptyline was preferred with isocarboxazid in 
Denmark [1]. 
Isocarboxazid must never be combined with SSRIs and most 
new antidepressants. However, a study on combined isocarboxazid-
mianserin treatment in 60 patients with endogenous depression showed 
that the two antidepressants effectively and safely could be combined 
from start of treatment [19].
A 56 year old female patient was admitted to hospital after a serious 
suicidal attempt. For years she had been treated with SSRIs without 
sufficient effect. She recovered with a series of ECT treatments, however, 
shortly afterwards relapsed. Treatment with nortriptyline was initiated. 
As she did not obtain full remission, isocarboxazid 30 mg, starting with 
10 mg, was added to the 150 mg nortriptyline and she soon recovered. 
Since then she had for more than 8 years been completely well without 
depressive symptoms, and following advice concerning foodstuff and 
other drugs without observed or reported adverse effects.
A 60 year old man was seen in the outpatient clinic with a 
serious major depression with suicidal ideation, which had gradually 
developed after he lost his job. Treatment with nortriptyline 150 mg was 
initiated, however, never resulted in full remission. Add-on treatment 
with lithium or quetiapine was without effect. Instead treatment with 
isocarboxazid was added gradually. At an add-on dose of 40 mg the 
depression had completely remitted, however, a dose of 20 mg was 
preferred, as the higher dose resulted in sexual dysfunction. On the 
latter add-on dose he was nearly without depressive symptoms and 
continued the combination therapy for years, also after he was back on 
the labour market again.
Mechanisms of Action and How Isocarboxazid is 
Metabolised
The MAOIs are divided into two main categories, hydrazine 
derivatives like isocarboxazid and phenelzine and non-hydrazine 
derivatives like tranylcypromine [3,20]. They are irreversible MAOIs, 
which means that new enzymes have to be synthesized before it is safe 
to change antidepressive treatment from isocarboxazid to an alternative 
antidepressant. This may take about two weeks. It has been suggested 
that a clinical response corresponds with at least 80% inhibition of 
the monoamine oxidases, though it was never fully studied in clinical 
practice. Nevertheless a clinical response depends on a daily dose above 
a certain threshold [20].
Furthermore they are classified in type A and type B MAOIs 
according to substrate specificity in the mammalian brain. 
Isocarboxazid is a type A MAOH, which inhibit the degradation of 
serotonin, noradrenalin and dopamin, and relevant for the discussion 
of diet restrictions also tyramin. 
Isocarboxazid is metabolized by hydrolysis in the liver to inactive 
metabolites (Figure 1). The liver enzyme carboxylesterase is the 
principal cause of the metabolism [21]. 
In contrast to most other antidepressants, among these SSRIs and 
TCAs the liver enzyme CYP2D6 is not involved in the metabolism. This 
means that isocarboxazid can be used in normal dosage also in case 
of genetic determined polymorphism with a defect CYP2D6 enzyme 
system. The number of persons in Denmark who are metabolising 
most antidepressants and other psychopharmaceutic drugs too slow 
are above 7% [22].
Adverse Effects
Isocarboxazid is normally well tolerated and in accordance with the 
literature and a recent Danish update the drug shows few side-effects. 
This applies also for the effect on the liver function, however, dizziness, 
headache, orthostatic hypotension and minor anticholinergic side 
effects may occur [2,14]. Sexual dysfunction has often been listed as 
one of the major problems of treatment with MAOIs, however, sexual 
complaints are difficult to validate, as loss of libido often is associated 
with depression [23]. Dose reduction may relieve the sexual dysfunction 
as the clinical case story above describes. 
Clinical use of isocarboxazid may be associated with the 
development of oedema around the ankles, hands, fingers, stomach 
and eyes. If severe, this adverse event may necessitate discontinuation 
of treatment. Clinical experience has found that pyridoxine (vitamin 
B6) supplement counteracts the tendency to develop oedema during 
treatment with some MAOIs, including isocarboxazid [24,25]. 







Figure 1: Isocarboxazid is metabolized by hydrolysis. In 
this process isocarboxazid is decomposed in two equal 
parts.
Figure 1: Isocarboxazid is metabolized by hydrolysis. In this process 
isocarboxazid is decomposed in two equal parts.
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to form a complex which inhibits pyridoxal kinase. This prevents the 
activation of pyridoxine to pyridoxal 5’-phosphate (PLP), thereby 
inhibiting numerous enzymatic reactions. Thus in a pilot study it has 
been shown that a supplement of pyridoxine in a daily dose of 100-200 
mg significantly may reduce the oedemas [25].
Interactions with Pharmaceutical Drugs and Foodstuffs
With the MAOIs simultaneous use of a number of drugs is 
contraindicated. This applies first of all for direct and indirect 
acting sympathomimetics like adrenalin, noradrenalin, ephedrine, 
amphetamine, methylphenidate, and others. This includes as well 
many asthma drugs, stimulants, certain cough and cold remedies 
and local anaesthetics with a vessel-constricting agent added. Also 
methadone should be omitted, as it inhibits the serotonin reuptake, 
and concomitant use of SSRIs is contraindicated because of risk of 
developing a serotonergic syndrome [2,20,26]. 
From the early 1960’ies it was observed that hypertensive episodes 
during treatment with MAOIs occurred with tyramine containing 
foodstuffs. Tyramine is formed from tyrosine in the process of maturing 
(cheese and pickled herrings), fermentation and putrefaction. All kind 
of cheese is in a stage of maturing, especially blue cheese, and only very 
fresh cheese contains very little tyramine [20,27]
The early MAOI diets recommended were unnecessarily restrictive. 
In fact, very few foods have sufficient tyramine content to approach 
the threshold of a serious hypertensive reaction [28]. A high-tyramine 
meal, however, is sufficient to increase blood pressure critically, when 
a substantial part of the monoamine oxidase has been inhibited. It may 
take only 8-10 mg of dietary tyramine to increase blood pressure when 
the monoamine oxidase is irreversibly “knocked out” by high doses of 
an MAOI [29]. In other words the interaction is dose dependent of as 
well the amount of tyramine as of the dose of isocarboxazid. 
The content of tyramine has been analysed in a number of 
European foods and menus and revealed overall considerably lower 
contents of tyramine than reported previously [30]. In accordance with 
these measurements a Canadian study from 2013 included on the list 
of foods to be avoided, all matured cheese, fermented or dry sausage, 
improperly stored meat or pickled herrings, broad been pods, all on-
tap beer, sauerkraut, marmite concentrated yeast extract and soy sauce. 
On the other hand the same study allowed all fresh cheese products, all 
fresh packed or processed meat, fish and poultry products, and wine in 
modest quantities [31]. The Danish agent has prepared an isocarboxazid 
foodstuff instruction in Danish, which corresponds with the Canadian 
recommendations and the instructions from FDA from 2014 [32,33].
Patients being treated with MAOIs have generally been informed 
to avoid foodstuff containing high quantities of tryptophan because of 
risk of developing a serotonin syndrome [34]. Thus delirious reactions 
have been observed in patients on steady-state treatment with MAOIs 
when a dose of commercial L-tryptophan above 1 gram was added [35]. 
The content of various amino acids including racemic tryptophan has 
been measured in more than 100 food items. Overall the content of 
tryptophan was very low, for example 18 mg/100 mg in raw, peeled 
bananas and 20 mg/100 g in cooked potatoes [36]. On a normal diet it 
is according to these measurements considered to be unlikely that toxic 
reactions to the combination of MAOIs and tryptophan may occur.
Discussion
Depression is one of to-day’s major health problems. Danish studies 
have shown that 3–4% of the population is suffering from moderate 
to severe depression [37] and furthermore the number of patients 
with atypical or treatment-resistant depression, who may potentially 
benefit from MAOIs, is substantial [31]. In Denmark it has thus 
been recommended that isocarboxazid ought to be included in the 
national guidelines for those patients who are resistant to conventional 
antidepressant treatment and ECT [2], which is in accordance with recent 
international reviews [28,31]. For unknown reasons isocarboxazid was 
not included in the latest revision of the Danish national guidelines from 
2007 on the treatment of unipolar depression [2].
Treatment with MAOIs like isocarboxazid is an assignment for 
specialists; however, the understanding of the mechanisms of action 
and how the drug is metabolized make the treatment rational, easy 
and safe. For that purpose a simple instruction has been written, 
containing general advice (Table 1). Each single patient in treatment 
with isocarboxazid is recommended to carry along this instruction at 
any time including when travelling abroad. The instruction which is 
written in Danish has been translated into English and a number of 
European and Middle East languages.
For more than 30 years a procedure as mentioned above for using 
isocarboxazid in Denmark has been maintained. This may be the reason 
for the scarcity of drug and food interactions reported in Denmark and 
to the best knowledge of the authors none leading to lasting morbidity. 
Therefore isocarboxazid is still a relevant option in treatment-resistant 
depression and we are to-day much better prepared than we were many 
years ago to use the drug with rational skills. 
Observational studies and more psychiatrists becoming familiar 
with the clinical use of the drug may be some of the future directions for 
the medication with isocarboxazid and for research to be recommended.
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